Immunological therapies for rheumatoid arthritis
Immunological therapies for rheumatoid arthritis
复制标题
DOI：
10.1093/bmb/ldh051
复制
发表时间：
2005-01-01
影响因子：
6.7
通讯作者：
Edwards, CJ
中科院分区：
文献类型：
--
作者：
Edwards, CJ
风湿性关节炎（RA）是一种慢性炎症性关节炎的滑膜关节，导致功能丧失和预期寿命缩短。在过去的10年中，RA的治疗取得了重大进展，包括更积极地使用疾病缓解抗风湿药物，以及针对RA免疫发病机制中重要分子和细胞的免疫疗法的发展。已经发现在细胞之间旅行的分子信使（细胞因子）是非常重要的。阻断细胞因子肿瘤坏死因子α（TNF-α）可显著改善RA、强直性脊柱炎、银屑病关节炎、银屑病和克罗恩病。细胞因子阻断剂的使用已经显示了免疫和炎症途径在许多炎症性疾病中共享的程度。还有一个重要的原则证明，即阻断单一细胞因子可以在炎症性疾病中产生深远的影响。
Rheumatoid arthritis (RA) is a chronic inflammatory arthritis of the synovial joints that causes loss of function and a shortened life expectancy. In the last 10 years there have been major advances in the treatment of RA, including more aggressive use of disease-modifying anti-rheumatic drugs and the development of immune therapies targeted to molecules and cells important in the immunopathogenesis of RA. Molecular messengers that travel between cells (cytokines) have been found to be of major importance. Blocking the cytokine tumour necrosis factor alpha (TNF-alpha) produces significant improvement in RA, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. The use of cytokine blockers has shown the extent to which immune and inflammatory pathways are shared in a number of inflammatory diseases. There has also been an important proof of principle that blocking single cytokines can produce profound effects in inflammatory diseases.